Figure 3 | Scientific Reports

Figure 3

From: Discovery of anti-Formin-like 1 protein (FMNL1) antibodies in membranous nephropathy and other glomerular diseases

Figure 3

ELISA assay for anti-FMNL1 serum levels in patients with MN. (A) Box plot showing the median and interquartile range value of serum for anti-FMNL1 in all subjects of study. Anti-FMNL1 was statistically significant more abundant in MN patientsanti-PLA2R1 negative compared to healthy donors and MN anti-PLA2R1 positive (P < 0.0001). (B) Box plot of serum anti-FMNL1 in MN patients stratified in function of anti-PLA2R1 positivity and their range of proteinuria after one year from hospitalization (< 0.3 g/d complete remission; > 0.3 g/d no complete remission). Anti-FMNL1 was statistically significant more abundant in MN patients anti-PLA2R1 negative in no complete remission compared with all other MN patients (P < 0.0001). Moreover, no difference was present in anti-FMNL1 titer between MN patients anti-PLA2R1 positive in complete remission or not and anti-PLA2R1 negative in complete remission. (C) ROC curve analysis for FMNL1 assay.

Back to article page